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ABSTRACT
Objective: To assess regional patterns of gray and white matter atrophy in familial Alzheimer dis-
ease (FAD) mutation carriers.
Methods: A total of 192 participants with volumetric T1-weighted MRI, genotyping, and clinical
diagnosis were available from the Dominantly Inherited Alzheimer Network. Of these, 69 were
presymptomatic mutation carriers, 50 were symptomatic carriers (31 with Clinical Dementia Rat-
ing [CDR] 5 0.5, 19 with CDR . 0.5), and 73 were noncarriers from the same families. Voxel-
based morphometry was used to identify cross-sectional group differences in gray matter and
white matter volume.
Results: Significant differences in gray matter (p , 0.05, family-wise error–corrected) were
observed between noncarriers and mildly symptomatic (CDR 5 0.5) carriers in the thalamus
and putamen, as well as in the temporal lobe, precuneus, and cingulate gyrus; the same
pattern, but with more extensive changes, was seen in those with CDR . 0.5. Significant
white matter differences between noncarriers and symptomatic carriers were observed in
the cingulum and fornix; these form input and output connections to the medial temporal lobe,
cingulate, and precuneus. No differences between noncarriers and presymptomatic carriers
survived correction for multiple comparisons, but there was a trend for decreased gray
matter in the thalamus for carriers closer to their estimated age at onset. There were no
significant increases of gray or white matter in asymptomatic or symptomatic carriers com-
pared to noncarriers.
Conclusions: Atrophy in FAD is observed early, both in areas commonly associated with sporadic
Alzheimer disease and also in the putamen and thalamus, 2 regions associated with early amyloid
deposition in FAD mutation carriers. Neurology 2013;81:1425–1433
GLOSSARY
AD 5 Alzheimer disease; ADNI 5 Alzheimer’s Disease Neuroimaging Initiative; aNC 5 asymptomatic noncarriers; CDR 5
Clinical Dementia Rating; DIAN5 Dominantly Inherited Alzheimer Network; EYO 5 estimated years to symptom onset; FA 5
fractional anisotropy; FAD 5 familial Alzheimer disease; FWE 5 family-wise error; GLM 5 general linear model; GM 5 gray
matter;NC5 noncarriers; PiB5 Pittsburgh compound B; pMut15 presymptomatic carriers; sMut15 symptomatic carriers;
sNC 5 symptomatic noncarriers; TIV 5 total intracranial volume; VBM 5 voxel-based morphometry; WM 5 white matter.
Recent failures of phase III trials1,2 in Alzheimer disease (AD) have provoked concerns that the
mild to moderate dementia stage may be too late for successful treatment.3,4 Arguably, an
effective therapy should be applied at the earliest stages, to slow pathology accumulation and
neurodegeneration before substantial irretrievable neuronal loss occurs. Consequently, research-
ers are designing prevention or secondary prevention studies.5,6 However, identifying and
recruiting at-risk individuals from the general population requires extensive and costly screening,
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with uncertainty that participants will go on to
develop AD. Alternatively, individuals carry-
ing an autosomal dominantly inherited muta-
tion for familial AD (FAD) could be targeted.
While rare, hundreds of mutation-carrying
families have been identified worldwide, with
early and relatively predictable ages at onset.
Effective therapeutic trials will require sensitive
measures of early-stage disease progression, for
which imaging shows great promise. Amyloid
deposition is evident using PET at least a
decade before symptomatic onset in FAD.7–9
Structural MRI reveals downstream consequen-
ces of neurodegeneration that appear closer to
symptom onset. At diagnosis of AD dementia,
hippocampi are 15% to 20% smaller than in
age-matched controls,10 diverging from normal
3 to 5 years earlier.11 Some brain regions have
produced conflicting results regarding the pres-
ence of an early increase in volume.9,12–17
Importantly, virtually all previous studies
considered a small sample (,25 participants)
with a few FAD mutations. We report a voxel-
based morphometry study on nearly 200 indi-
viduals from the international Dominantly
Inherited Alzheimer Network (DIAN),9 which
aims to understand the temporal ordering of
abnormalities in FAD.
METHODS Standard protocol approvals, registrations,
and patient consents. All aspects of the study were approved by
the institutional review boards for each of the participating sites in
DIAN. All participants provided written informed consent.
Participants. All participants were recruited as part of the DIAN
study, which aims to enroll up to 400 individuals at risk for one of
the genetic mutations linked with FAD. Full details of participating
sites, enrollment, and assessments in DIAN have been published.18
As part of obtaining the family history, a semistructured interview is
conducted to determine the affected parent or sibling’s age at onset.
The estimated years to symptom onset (EYO) has been defined as
the difference between this expected age at onset and the partic-
ipant’s current age; negative values indicate that an individual is
younger than his or her expected age at onset. Genetic testing is
performed to determine the presence of a mutation, but genetic
data are provided only to those performing the analysis. This pre-
serves patient confidentiality and ensures that both the participants
and the clinicians assessing them remain blind to their genetic
status.
At the time of analysis, 242 participants in the DIAN cohort
were available from the third data cutoff (February 29, 2012). Of
these, 192 had the complete genetic, demographic, and cognitive
information required. Participants were divided into 3 groups
based on the presence of a mutation and their Clinical Dementia
Rating19 (CDR): 73 were noncarriers (NC); 69 carriers were clas-
sified as presymptomatic (pMut1) as their CDR was 0, indicat-
ing cognitive normality; and 50 carriers with a CDR of 0.5 or
higher were defined as symptomatic (sMut1). Four NC had non-
zero CDR, unlikely to be due to coincidental sporadic AD since
they were all under 45 years of age, but perhaps arising from non-
AD causes such as depression; these therefore formed a fourth
group (symptomatic NC [sNC]) separate from the 69 asymptom-
atic NC (aNC).
MRI scanning. Participants underwent volumetric T1-weighted
MRI, using the accelerated sequence defined in the Alzheimer’s
Disease Neuroimaging Initiative second phase (ADNI-2).20 Indi-
viduals were scanned twice during a session, safeguarding against
one poor-quality image. Sites used 3 different types of qualified 3-T
scanner: Siemens Tim Trio, Siemens Verio, and Philips Achieva.
Matching between scanners and image quality control were per-
formed according to the ADNI protocol by the imaging core.21
Image analysis. Voxel-based morphometry (VBM) was carried out
using the SPM8 package (Statistical Parametric Mapping;
http//www.fil.ion.ucl.ac.uk/spm) running on Matlab 7.12
(MathWorks; http://www.mathworks.com). Gray matter (GM)
and white matter (WM) probability maps were obtained from the
volumetric images using the tissue segmentation tools in the VBM8
toolbox (University of Jena; http://dbm.neuro.uni-jena.de) to obtain
better segmentation of subcortical GM. One individual from the
sMut1 group was excluded due to extensive WM pathology.
Spatial normalization was performed using DARTEL,22 modulating
normalized tissue maps to preserve their original volumes. Both scans
from the imaging session were segmented, but only one from each
individual was used in subsequent analysis (chosen as that with
the higher SPM segmentation objective function). Images were
smoothed using a Gaussian kernel with 6 mm full-width at half-
maximum, balancing the detection of small-scale anatomical
differences while ameliorating misalignment. GM and WM
analysis masks were created by averaging individual smoothed
normalized GM and WM segmentations and dichotomizing at
a value of 0.2.23
Data were fitted with a general linear model (GLM) in SPM8,
containing the following terms: a 4-level group factor (aNC,
sNC, pMut1, sMut1); a 10-level factor representing the acqui-
sition sites; a 2-level factor indicating the presence of an APOE e4
allele (a well-established risk factor for sporadic AD24,25); a factor
for gender; a covariate for total intracranial volume (TIV); and a
covariate for EYO interacting with the group factor. TIV was
calculated by summing GM, WM, and CSF volumes from the
VBM8 segmentation. Because multiple participants from the
same families enrolled in DIAN, family membership was mod-
eled as a random effect, permitting covariance among relatives.
Contrasts of the GLM parameters were used to test for differences
among the 3 main diagnostic groups (aNC, pMut1, and
sMut1) and among the 10 sites (F contrasts with 2 and 9 numer-
ator degrees of freedom, respectively). Contrasts were also used to
detect pairwise differences between diagnostic groups or changes
due to APOE status (one-tailed t contrasts). Multiple comparison
correction was performed to control voxel-level family-wise error
(FWE) at p , 0.05, though some results are shown at an uncor-
rected level of p , 0.001 (in some cases alongside unthresholded
effect maps) to provide better characterization of patterns not
reaching significance.
Forthcoming clinical trials may recruit mutation carriers either
with mild symptoms or near to their expected onset. Therefore, we
performed additional analyses where the carrier groups were divided
into smaller subgroups according to criteria relevant for clinical tri-
als. The sMut1 group was divided according to clinical severity as
assessed by CDR: 31 individuals with CDR 5 0.5 and 19 with
CDR . 0.5. The pMut1 group was divided into 3 subgroups
1426 Neurology 81 October 15, 2013
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
based on EYO: 30 individuals more than 15 years away, 24
between 15 and 6 years away, and 15 less than 6 years from
expected onset. As the EYO variable defined these subgroups, the
EYO group interaction was replaced with a simple age covariate in
this analysis.
RESULTS Demographics of included participants are
summarized in table 1. On average, the presymptom-
atic carriers (pMut1) were more than 10 years away
from their expected symptom onset; 80% of carriers
have a mutation in the presenilin-1 gene (PSEN1), 8%
presenilin-2 (PSEN2), and 12% amyloid precursor
protein (APP).
Figure 1 shows the F test (p , 0.05, FWE cor-
rected) for significant GM differences among the 3
groups of interest: the GM volumes were lower in car-
riers in 1) the temporal lobe, both medially in the
region of the hippocampi and laterally in the temporal
neocortex; 2) precuneus; 3) cingulate gyrus, primarily in
the posterior region; 4) putamen; and 5) thalamus. For
each of these regions, figure 1 provides an illustrative
(though circular26) plot of the linear fit of GM volume
to EYO at the voxel with the peak F test statistic. A
similar F test for WM differences is shown in figure 2.
There were significant reductions in the fornix and
cingulum, projections to the hippocampus, precuneus,
and posterior cingulate. Table e-1 on the Neurology®
Web site at www.neurology.org details these GM
and WM findings. When examining the pairwise
comparisons, the t test for GM decrease between aNC
and sMut1 (figure e-1) looks similar to the overall
group test. No findings survived FWE correction
when comparing aNC and pMut1.
We performed reverse contrasts to test for GM
and WM increases between NC and carriers. For
sMut1, there was one area of significantly increased
GM on the boundary between the splenium of the
corpus callosum and the lateral ventricle. There were
2 findings for WM: the inferior boundary of the cau-
date and the inferior boundary of the accumbens/
putamen. There were no significant increases
between aNC and pMut1.
Figure 3 provides GM results when the sympto-
matic carrier group is subdivided according to CDR.
Findings of decreased GM are present even in the
mildest symptomatic subgroup (CDR5 0.5). Differ-
ences are more widespread in the CDR . 0.5 sub-
group despite the smaller sample size. When directly
comparing these 2 subgroups, there are significant
findings of decreased GM in the more affected
(CDR . 0.5) subgroup within the medial temporal
lobe and posterior cingulate.
No findings survived FWE correction when com-
paring EYO-stratified presymptomatic carriers to
NC, but there were trends for carriers to show lower
GM volume nearer to their expected age at onset.
Figure 4 illustrates this trend and provides the effect
maps from each EYO subgroup vs NC. In the sub-
group less than 5 years away from onset, there is a
suggestion of reduced GM in the thalamic areas, and
in neocortical areas of the lateral temporal lobe.
DISCUSSION VBM was performed on volumetric
MRI from a large cohort of individuals at risk for,
or mildly affected by, autosomal dominantly inher-
ited AD from the DIAN study; 192 individuals were
studied—a much larger sample than prior FAD stud-
ies. The larger sample size in this study can provide a
consensus pattern of atrophy, whereas single site stud-
ies have provided variable results, likely due to unique
patterns of atrophy in the smaller cohorts of muta-
tions and families. We were careful in attempting to
account for heterogeneity due to multiple sites and
scanners: there were significant effects of site in the
peripheral areas of the brain and near the thalamus for
Table 1 Demographics of DIAN participants used in this study
Group N % Female Age, mean (SD) EYO, mean (SD) % PSEN1 mutations
Noncarriers 73 56 40.6 (8.9) NA NA
Presymptomatic carriers
Total 69 58 34.1 (8.9) 213.1 (8.4) 77
£215 EYO 30 53 28.1 (6.7) 220.7 (4.0) 70
215 to 26 EYO 24 58 37.1 (5.1) 211.1 (2.7) 83
‡25 EYO 15 60 41.3 (9.7) 21.1 (3.7) 80
Symptomatic carriers
Total 50 58 45.6 (10.5) 0.1 (8.0) 84
CDR 5 0.5 31 61 43.4 (11.0) 21.5 (8.2) 84
CDR > 0.5 19 53 49.2 (8.6) 2.7 (7.1) 84
Abbreviations: CDR 5 Clinical Dementia Rating; DIAN 5 Dominantly Inherited Alzheimer Network; EYO 5 estimated years
to symptom onset; NA 5 not applicable.
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GM and in the inferior frontal lobe near the frontal
pole for WM (figure e-2), but no significant site-by-
group interaction. These findings are mainly in areas
frequently affected by differences in hardware and
susceptibility artifacts. The site effects show little sim-
ilarity to the main results, but nevertheless demon-
strate the importance of modeling this factor.
We found evidence of GM reduction in 3 areas
that are well-recognized in the sporadic (late-onset)
AD literature: the temporal lobe, precuneus, and cin-
gulate. There were also signs of early change in the
putamen and thalamus—structures not typically asso-
ciated with sporadic AD, though such an association is
documented when comparing patients with AD with
elderly subjects who have no objective memory
decline.27,28 In this study, we observed differences in
these structures at earlier stages of the disease, with
carriers at CDR 5 0.5. Recently, decreased volumes
and increased fractional anisotropy (FA) of the thala-
mus and caudate were reported in presymptomatic
PSEN1 mutation carriers29 (11 participants in that
study were also included the current work, though
not using the same volumetric T1 scans). These results
are interesting in light of amyloid PET studies of FAD
that report increased uptake in these areas, which
might be the earliest regions of amyloid deposition
for some individuals. Striatal uptake of Pittsburgh
compound B (PiB) was reported for 5 asymptomatic
Figure 1 Significant group differences in gray matter volume
An F test was performed among the 3 main groups (asymptomatic noncarriers [NC]; presymptomatic mutation carriers [pMut1]; symptomatic mutation carriers
[sMut1]), and all results shown are family-wise error corrected. The peak voxel is highlighted in 6 regions: (left column, top to bottom) precuneus,medial temporal
lobe, temporal neocortex; (right column, top to bottom) cingulate, thalamus, putamen. For each voxel highlighted in the 6 slices, a linear fit of the gray matter
volume with respect to expected years from symptom onset is plotted. Green lines indicate NC, blue lines indicate pMut1, and red lines indicate sMut1.
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and 5 symptomatic carriers with 2 PSEN1mutations8;
uptake in cortical areas was also increased compared to
controls, though not as much as in sporadic late-onset
AD. A similar study of 7 asymptomatic and sympto-
matic patients with 3 different PSEN1 mutations
found that striatal PiB uptake was not increased com-
pared to sporadic AD, but uptake was increased in the
thalamus.7 However, it remains an open question
whether the presence of amyloid alone directly causes
atrophy, or whether it is a downstream effect mediated
by tau or requiring some other mechanism.30–32
WM was reduced in both input (cingulum) and
output (fornix) connections to the hippocampi. This
is consistent with reported decreases in cross-sectional
area and FA of the fornix columns in FAD mutation
carriers.33 We also observed WM differences in areas
close to the posterior cingulate and precuneus. How-
ever, caution should be exercised when interpreting
WM alterations identified using VBM. T1-weighted
images provide little anatomical information about
WM tracts, so spatial normalization is driven by
matching detailed convolutions in GM and the ven-
tricular boundary. Partial volume effects, especially in
the small medial temporal structures, could also affect
the findings. As most of the WM changes overlap
areas that predominantly contain GM, these results
may reflect GM atrophy rather than actual WM dif-
ferences. Future studies using tensor-based mor-
phometry or diffusion-weighted imaging should
provide a more complete picture of the WM altera-
tions in FAD.
The majority of the differences observed in this
study were in symptomatic mutation carriers. Most
of these carriers have a CDR of only 0.5, which usu-
ally indicates mild symptoms, insufficient to interfere
severely with everyday activities. GM volume reduc-
tion was still detectable when the symptomatic car-
riers with CDR greater than 0.5 were excluded.
This suggests that the results were not being driven
by the smaller number of more affected individuals,
but that changes are already occurring at the time
of the first signs of cognitive impairment in FAD.
This group is also likely to have a more homogenous
pathology than analogous groups in the sporadic AD
cohorts.
No significant findings of either increased or
decreased GM were present in the presymptomatic
carrier group, though a trend toward progressive
Figure 2 Significant group differences in white matter volume
An F test was performed among the 3 main groups, and all results shown are family-wise error corrected. The peak voxel is highlighted in 4 regions: (left
column, top to bottom) cingulum/perforant path, cingulum (near posterior cingulate); (right column, top to bottom) cingulum (near precuneus), fornix. For each
voxel highlighted in the 6 slices, a linear fit of the gray matter volume with respect to expected years from symptom onset is plotted. Green lines indicate
asymptomatic noncarriers (NC), blue lines indicate presymptomatic mutation carriers (pMut1), and red lines indicate symptomatic mutation carriers (sMut1).
Neurology 81 October 15, 2013 1429
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
atrophy was suggested by the effect maps of the EYO-
based subgroups. Another suggestion of increasing
atrophy near to onset is observed when plotting the
linear fit of the GM volumes with respect to EYO,
shown for key areas in figure 1. Given reports that
presymptomatic FAD may feature increased GM vol-
ume,13,14 we also looked at reverse contrasts for areas
of increased GM; no findings survived FWE correc-
tion. Findings of increased volume may be related to
specific mutations and are likely to be subtle in com-
parison to decreases caused by neurodegeneration,
requiring more sensitive measures to identify them.
In the symptomatic mutation group, there were some
findings of increased volume relative to NC, but
given the locations (splenium for GM, caudate and
accumbens for WM) and low tissue probabilities,
these may reflect partial volume effects.
The earliest point at which GM changes can be
observed presymptomatically still needs to be deter-
mined. Two structural MRI studies have been per-
formed on the PSEN1 E280A Colombian kindred
to identify changes in presymptomatic carriers com-
pared to age-matched controls. One study17 using
VBM on very young carriers—approximately 20 to
25 years from expected age at onset—found an area of
GM decrease in the parietal lobe, which survived cor-
rection for multiple comparisons only when using a
smaller search volume based on findings for patients
with sporadic AD. The other study15 used carriers
much closer (;6 years) to expected onset and
observed changes in cortical thickness of the precu-
neus, angular gyrus, and superior parietal lobule. In a
similar sized cohort (25 carriers, 10 NC),14 there was
evidence of GM volume loss in the thalamus and
putamen for 9 carriers with CDR of 0, who were
on average 15 years before their family’s median age
at diagnosis. It is not clear how this relates to the time
of earliest symptoms, as more than half reported sub-
jective memory complaints.
Our results indicate that widespread GM differen-
ces might only occur relatively close to the onset of
symptoms. In the at-risk group that we studied, there
were only 15 presymptomatic carriers within 5 years
of expected age at onset. Having only a small sample
in this crucial risk window limits the power to detect
changes. VBM is also often less sensitive than targeted
volumetric measurements of key structures. Hippo-
campal volume reductions have been observed as
early as 10 years before expected onset in the DIAN
cohort.9 This finding of earlier change could be due
to methodologic differences (specifically measuring
hippocampal volume as opposed to VBM with cor-
rection for multiple comparisons); in addition, the
finding may have been partially driven by affected
carriers who were younger than their expected age
at onset. We plan to use the results from this VBM
Figure 3 Gray matter differences in symptomatic carriers subgrouped by clinical dementia rating
Three pairwise tests are shown: (A) Differences between asymptomatic noncarriers (NC) and symptomatic mutation carriers (sMut1) with Clinical Dementia
Rating (CDR) . 0.5 (t test, family-wise error [FWE] corrected p , 0.05), (B) NC and sMut1 with CDR 5 0.5 (t test, uncorrected p , 0.001), and (C) sMut1
groups, CDR 5 0.5 vs CDR . 0.5 (FWE corrected p , 0.05). In (B), blue circles indicate the regions where the findings survived FWE correction.
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analysis to determine which structures would be of
interest for subsequent volumetric analyses.
Furthermore, estimated onset will be inaccurate,
due to both true variability in the age at onset over gen-
erations and imprecision in determining parental
onset. Studies that have information on individuals’
actual clinical onsets (i.e., longitudinal studies tracking
mutation carriers from presymptomatic to sympto-
matic stages) are likely to have greater precision in
defining the location and timing of losses. Importantly,
as part of the DIAN study, the participants studied
here will have continued follow-up assessments,
including imaging. We expect these longitudinal
assessments to enable more sensitive measurement of
location, timing, and rate of change in the presymp-
tomatic stages.
In light of previous observations regarding possible
clinical,34 imaging,35 molecular,36,37 and neuropatho-
logic differences between individuals with APP and
PSEN1mutations, and among individuals with distinct
PSEN1mutations,38 atrophy patterns may differ among
these subgroups. Since this study predominantly con-
tains PSEN1 mutation carriers, it is difficult to deter-
mine what differences might be present in FAD caused
by APP, PSEN1, or PSEN2mutations. As more partic-
ipants enroll, it will become clearer whether there are
indeed differences in the atrophy patterns among these
3 genes (or even among the more common specific
point mutations within these genes). There were no
significant findings related to carrying an APOE e4
allele, which could be due to a difference in the roles
that the APOE gene plays in familial and sporadic AD.
Brain-wide analysis using VBM indicates that
individuals with FAD, even when showing the earliest
of symptoms, already have significantly less GM in
brain areas previously linked to AD, but there also
appear to be losses in the putamen and thalamus.
This is consistent with prior reports of amyloid depo-
sition in these structures in FAD. These results pro-
vide further insight into the pattern of atrophy in
FAD, which may help to inform decisions regarding
volumetric MRI biomarkers for clinical trials.
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